阴道油性胶囊与栓剂黄体期支持在辅助生殖治疗中的比较:一项42 291个周期的多中心队列研究
该回顾性队列研究分析了英国14家Care Fertility诊所2017年1月至2022年12月的42 291个辅助生殖治疗周期,比较阴道油性胶囊(600-800 mg/天)与栓剂(800 mg/天)用于黄体期支持的临床结局。结果显示,在新鲜IVF/ICSI周期和激素替代冻胚移植周期中,油性胶囊组的活产率均高于栓剂组,冻胚周期中油性胶囊组的流产率更低。作者认为需要一项适当把握度的随机对照试验直接比较两者。
要点
- 在IVF/ICSI新鲜周期中,油性胶囊组活产率34.3% vs 栓剂组27.8%(aRR 1.11,95%CI 1.04-1.19;P<0.001)。
- 在HRT-FET周期中,油性胶囊组活产率36.7% vs 栓剂组32.9%(aRR 1.09,95%CI 1.04-1.14;P<0.001)。
- 调整分析中,仅HRT-FET周期流产率差异有统计学意义(aRR 0.87;95%CI 0.82-0.93)。
核心结论
- 研究结果表明,在新鲜和冻融周期中,阴道油性胶囊相比栓剂用于黄体期支持可获得更高的活产率;在冻融周期中,油性胶囊组的流产率更低。
研究设计与样本
- 回顾性队列研究,纳入2017年1月至2022年12月英国14家Care Fertility诊所接受刺激IVF/ICSI新鲜胚胎移植和自体激素替代冻胚移植周期的女性。
- 共分析42 291个周期,其中25 738个周期仅使用阴道油性胶囊,16 553个周期仅使用栓剂。
- 油性胶囊剂量为600-800 mg/天,栓剂剂量为800 mg/天;主要结局为活产和流产。
- 采用多变量回归分析,调整了女性年龄、BMI、种族、卵巢储备、不孕持续时间和原因、刺激方案、既往周期数、获卵数、移植胚胎数、既往活产和既往流产。
主要发现
- 在IVF/ICSI组中,油性胶囊组活产率34.3% vs 栓剂组27.8%(aRR 1.11;95%CI 1.04-1.19;P<0.001)。
- 在HRT-FET组中,油性胶囊组活产率36.7% vs 栓剂组32.9%(aRR 1.09;95%CI 1.04-1.14;P<0.001)。
- 粗分析中,油性胶囊组流产率低于栓剂组:IVF/ICSI周期13.4% vs 14.5%(P<0.05),HRT-FET周期17.2% vs 19.7%(P<0.001)。
- 调整分析中,流产率的统计学显著差异仅见于HRT-FET周期(aRR 0.87;95%CI 0.82-0.93)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这是一项回顾性队列研究。
- 尽管对混杂因素进行了广泛调整,仍可能存在残余混杂。
- 需要一项适当把握度的随机对照试验直接比较这两种药物,重点关注临床疗效,以确定一种是否优于另一种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the effect of progesterone administered via vaginal oil capsules versus pessaries, on clinical outcomes, when used for luteal phase support (LPS) in ART? SUMMARY ANSWER: Our study findings indicate a higher live birth rate with vaginal oil capsules compared with pessaries, in both fresh and frozen cycles; in the frozen cycles, a lower miscarriage rate was observed with vaginal oil capsules compared with pessaries. WHAT IS KNOWN ALREADY: Sufficient LPS, with exogenous progesterone, is essential during ART to improve implantation and pregnancy rates. Micronized vaginal progesterone (MVP) is the most commonly used form of luteal support worldwide. There are no head-to-head comparisons of vaginal oil capsules versus pessaries, with a focus on clinical efficacy, for LPS. STUDY DESIGN, SIZE, DURATION: Retrospective cohort study of patients who completed ART cycles with either only vaginal oil capsules 600-800 mg/day or only pessaries 800 mg/day for LPS. Primary outcomes were live birth and miscarriage. Data for fresh IVF/ICSI cycles and frozen embryo transfer cycles with hormone replacement therapy (HRT-FET) were analysed separately. Multivariable regression analyses were performed with adjustment for female age, BMI, ethnicity, ovarian reserve, duration and cause of subfertility, stimulation protocol, number of previous cycles, number of oocytes, number of embryos transferred, previous live births, and previous miscarriages. PARTICIPANTS/MATERIALS, SETTING, METHODS: Our study population consisted of women undergoing treatment across 14 Care Fertility clinics in the UK, from January 2017 to December 2022. We included women with stimulated IVF/ICSI cycles with fresh embryo transfer and autologous HRT-FET cycles. A total of 42 291 cycles were analysed; vaginal oil capsules were exclusively used in 25 738 cycles and pessaries exclusively in 16 553 cycles. MAIN RESULTS AND THE ROLE OF CHANCE: In the IVF/ICSI group, the live birth rate was higher in those taking vaginal oil capsules compared with pessaries: 34.3% vs 27.8%; adjusted risk ratio (aRR) 1.11 (95% CI 1.04-1.19; P < 0.001). In the HRT-FET group, the live birth rate was also higher in those taking vaginal oil capsules compared to pessaries: 36.7% vs 32.9% (aRR 1.09; 95% CI 1.04-1.14; P < 0.001). The miscarriage rate was lower in those taking vaginal oil capsules compared to pessaries for both IVF/ICSI (13.4% vs 14.5%, P < 0.05) and HRT-FET cycles (17.2% vs 19.7%, P < 0.001) in the crude analysis. The adjusted analysis for miscarriage found a statistically significant difference only for HRT-FET cycles (aRR 0.87; 95% CI 0.82-0.93). LIMITATIONS, REASONS FOR CAUTION: This is a retrospective cohort study. Whilst we have extensively adjusted for confounding, there can still be residual confounding. WIDER IMPLICATIONS OF THE FINDINGS: An appropriately powered randomized controlled trial directly comparing the two drugs, focusing on clinical efficacy, is required to determine if one is superior to the other. STUDY FUNDING/COMPETING INTEREST(S): This study has been delivered through the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC). R.K.D.S. is in receipt of honoraria for lectures and presentations from Ferring Pharmaceuticals and Besins Healthcare UK. R.K.D.S. has received travel support from IBSA Pharma and Theramex UK and payment for participation on an advisory board for educational meetings for Ferring Pharmaceuticals and IBSA Pharma. A.C. has contributed to the scientific advisory boards of Ferring Pharmaceuticals, Theramax UK, Besins Healthcare UK, and Organon Pharma UK. M.K. has received travel support from Besins Healthcare UK and Merck. A.H.B. is on an advisory board and has received speaker fees from NovoNordisk Pharmaceuticals and is a shareholder at Care Fertility UK and Care Fertility Leeds. T.B. is in receipt of honoraria for lectures and presentations from Merck and Gedeon Richter. T.B. has received travel support from IBSA Pharma, Vitrolife, and Theramex and payment for participation on an advisory basis for IBSA Pharma and Conceivable Life Sciences. A.R. has received honoraria for lectures and presentations from Gedeon Richter. A.R. has received travel support from Gedeon Richter and payment for participation on an advisory board for educational meetings for Ferring Pharmaceuticals. V.S. has received travel support from IBSA Pharma and payment for educational meetings and participation in an advisory role for Theramex. TRIAL REGISTRATION NUMBER: n/a.
引用
- Dhillon-Smith RK, Khairy M, Bamford T, et al. A comparison of progesterone via vaginal oil capsules versus pessaries for luteal phase support in assisted reproduction treatment: a multicentre cohort study of 42 291 cycles. Hum Reprod. 2026. PMID: 41270285. doi:10.1093/humrep/deaf219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。